Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Biochemistry > Platelet Biohem And Fibrin Production And Inhibition > Flashcards

Platelet Biohem And Fibrin Production And Inhibition Flashcards

1
Q

Primary hemostasis

A

. Formation of a platelet plug

. Initiated in response to a vascular injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Platelets

A

. Cell fragments derived from megakaryocytes
. Maintain vascular integrity through primary hemostasis
. Provide surface to promote coagulation cascades (secondary hemostasis)
. Produces mediators to promote healing (PDGF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Platelet derived growth factor (PDGF)

A

Activates Tyr kinase to promote cell proliferation and wound healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why do intact endothelial cells not interact with platelets?

A

. Cells and platelets both have net negative surface charges and may repel each other
. Cells synthesize factors that inhibit hemostasis and platelet aggregation (prostacyclin, thrombomodulin, heparin sulfate, plasminogen activators, NO, ADPase )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Formation of primary platelet plug

A

. Subendothelial ECM glycoproteins are exposed (collagen, vWF)
. Platelets adhere to glycoproteins or Gp receptors
. Adherence induces signal transduction across platelet membrane leading to activation and release of coagulation mediators (ADP and TXA2)
. Activate platelets recruit other platelets and aggregate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Gp receptors

A

. Gp that binds to collagen in subendothelium
. Gp that binds vWF in suendothelium
. Gp II-IIIa: binds fibrinogen in blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Gp IIb-IIIa is a member of the ____ family

A

Integrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Platelet aggregation

A

. Activated platelets undergo conformational change in Gp IIb-IIIa allowing them to bind to fibrinogen w/ high affinity
. Binding to fibrinogen and thrombin stimulates additional platelet aggregation through platelet-platelet interaction
. Bound fibrinogen is enzymatically cleaved to fibrin through coagulation cascades (secondary hemostasis)
. Fibrin becomes entwined in and stabilizes primary hemostasis plug creating secondary plug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Thrombin

A

. Very potent inducer of platelet aggregation
. Product of hemostasis
. Induces further platelet aggregation and the release of agents like TXA2 and ADP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bernard-Soulier disease

A

. Platelet disorder

. Defect in Gp Ib-IX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Glanzmann thrombasthenia

A

. Platelet disorder

. Defect in Gp IIb-IIIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Von willebrand disease

A

. Deficiency/defect in VWF
. Most common bleeding disorder
. Autosomal dominant gene on chromosome 12
. Usually no treatment unless person is going into surgery
. Usually noticed first during dental procedures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Aspirin

A

. Irreversible inhibitor of COx in platelets
. Prevents inhibited platelet from producing TXA2
. Does not thin the blood
. Not an anticoagulant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Thromboxane A2 (TXA2)

A

. Very potent inducer of platelet aggregation

. Required for formation of platelet aggregates and platelet plug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Platelet receptor inhibitors

A

. Agents bind to glycoprotein (Gp) recents on platelets and prevent binding to normal ligand
.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

T/F platelet plug is not stable

A

T, will not stay in place w/o reinforcement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Intrinsic coagulation pathway

A

. All required components in plasma

. Plasma + phospholipid of platelet -> fibrin for stable clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Extrinsic coagulation pathway

A

. Requires external factor (tissue factor) for fibrin formation
. Must add something to plasma for clot to form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Extrinsic pathway of coagulation ____ the process while intrinsic pathway _____ the process

A

. Extrinsic initiates

. Intrinsic continues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

T/F proteases in coagulation are found in plasma as zymogens

A

T, when active add a to the end of factor name (factor X to factor Xa when active)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is needed for proper zymogens synthesis of serine proteases

A

. Vit. K

22
Q

Steps in initiation of extrinsic pathway

A

1: vascular injury
2: tissue factor (TF) combines w/ zymogens to form factor VII
3: factor VII-TF complex formed
4: inactive complex turned into VIIa-TF active complex, Ca needed, any active proteases can act on inactive complex to perform conversion
5: Factor X converted to Xa by active complex
6: Xa converts prothrombin (factor II) to thrombin (IIa), needs Ca, phospholipids from platelet membrane, and factor Va as cofactor
7: thrombin converts fibrinogen to fibrin, Factor XIII to XIIIa (needs Ca),
8: factor XIIIa (transglutaminase) cross links fibrin

23
Q

Steps in continuations/amplification of clotting process

A

1: thrombin converts factor XI to XIa
2: XIa converts factor IX to IXa (also produced by VIIa-TF complex)
3: XIa converts X into Xa in rxn that requires VIIIa as cofactor (thrombin activates VIII to VIIIa)
4: Xa w/ cofactor Va converts prothrombin to thrombin (common pathway w/ extrinsic), existing thrombin converts V to Va for cofactor

24
Q

Deficiency of factor VIII results in ____

A

Hemophilia A

25
Q

Deficiency in factor IX causes ____

A

Hemophilia B

26
Q

Tissue factor pathway inhibitor (TFP I)

A

. Protease inhibitor that inhibits activity of VIIa and Xa
. Pool of TFP I assoc. w/ endothelial cell surface
. Helps to contribute to non-thrombogenic properties of endothelial cell
. Binds to Xa, then TFP I-Xa complex can bind to VIIa/TF complex to make a complex that can’t activate coagulation
. Deficiency may be related to protein S deficiency

27
Q

Antithrombin

A

. Protease inhibitor that irreversible inhibits thrombin and Xa and IXa
. Can inhibit VIIa and XIa when they are bound to certain cofactors
. Inhibition faster in presence of heparan sulfate (in subendothelium) and heparin (drug)

28
Q

Heparin

A

. Glycosaminoglycan (like heparan sulfate)
. Low molecular weight heparin can activate antithrombin to inhibit factor Xa but not thrombin
. Standard heparin is potent and inactivates thrombin as well and achieves rapid anticoagulation

29
Q

Protein C/S pathway

A

. Activated protein C destroys cofactors, Va and VIIIa
. Thrombin binds to thrombomodulin on endothelium
. Protein C binds and is converted by thrombin to activated protein Ca
. Ca and cofactor protein S cleave and destroy Va and VIIIa

30
Q

Deficiency in what things is a risk factor for thrombosis

A

. Antithrombin deficiency (inc. risk not well known)
. Protein Ca deficiency (5-10 fold greater risk)
. Protein S deficiency (5-1o fold greater risk)
. Mutant form V Leiden instead of factor V

31
Q

Factor V Leiden

A

. 5% North American whites are heterozygous
. 4-8 fold greater risk for DVT in heterozygous, 80-fold higher in homozygous
. Change (Arg -> Gln) in factor V is mutation
. protein Ca can’t cleave it bc cleavage site is removed w/ mutation
. Remains active longer leasing to excess coagulation

32
Q

Prothrombin mutation (Factor II mutation)

A

. 2-3% whites have it
. 2-3x greater risk for DVT
. Polymorphism located in noncoding region of prothrombin gene (guanine replaced w/ adenine where polyA tail attached pre-mRNA)
. Causes inc. prothrombin production bc more stable mRNA
. Excess prothrombin contributes to hypercoagulability

33
Q

Non O blood group risk for clot

A

. 2 fold inc. risk compared w/ O type
.VWF levels 25% higher in non-O types
. When combined with another inherited coagulopathy can inc. Risk by 7-fold

34
Q

Elevated homocysteine affect on thrombosis risk

A

. Assoc. w/ clot
. Inc. in homocysteine from vit. B, folate deficiencies, kidney disease, low level thyroid hormones, psoriasis, and antiepileptic drugs
. Genetic variant of Mehtylenetetrahydrofolate (MTHF) reductase causes impairment of folate processing and inc. homocysteine

35
Q

Fibrinolysis

A

. Breakdown of fibrin clot
. Factors involved require fibrin for binding and must be biosynthesized causing time delay in initiation after vascular injury
. Initiation stimulated from stasis as result of presence of clot
. Plasminogen activates to plasmin via tissue-PA and urokinase PA
. Plasmin cleaves fibrin to form D-dimers of fibrin degradation products

36
Q

Tissue-PA (t-PA)

A

. Released from activated endothelial cells following its biosynthesis that is stimulated by activation of endothelial cell
. Binds to fibrin clots and activated plasminogen to plasmin by specific bond cleavage

37
Q

Inhibitors that control extent and timing of fibrinolysis

A

. Alpha2-antiplasmin that inhibits plasmin

. PAI-1 and 2 that inhibit t-PA and u-PA

38
Q

Coronary artery thrombosis

A

. Central mechanism in pathogenesis of MI

39
Q

Venous thrombosis

A

. Frequent complication of common medical disorders including MI, CHF, COPD, and stroke

40
Q

Thromboembolism

A

. Frequently seen after surgical procedures, esp. in obese patients, those w/ cancer, or prior thromboembolic episodes
. When high risk, incidence of DVT is 20%, pulmonary embolism is 2%, and fatal pulmonary embolism is 1%
. High risk in elderly patients

41
Q

Platelet receptor inhibitors

A

. Plavix (clopidogrel)
. GpIIb-IIIa inhibitors (REO PRO, AGGRASTAT)
. Bind to platelet receptors inhibiting platelet adhesion and aggregation

42
Q

Heparin complications

A

. Bleeding

43
Q

How is heparin neutralized?

A

Protamine

44
Q

Heparin-induced thrombocytopenia

A

. Immune reaction that induces clotting

45
Q

Warfarin

A

. Inhibits K-dependent gamma-carboxylase in liver that is important in zymogen production of prothrombin, factor VII, IX, and X by competing with K as cofactor
. Impairs coagulation because gamma-carboxylation is needed for zymogens to bind to Ca
. Slower than heparin
. Only acts on factors synthesized after drug administration, pre-existing coagulation factors will remain functional

46
Q

Warfarin complication

A

Bleeding

. Giving vit. K reverses effects of warfarin if bleeding is risk

47
Q

Direct thrombin inhibitors

A

. Argatroban, angiomax, and pradaxa

. Reversible bind to thrombin active site

48
Q

Factor Xa inhibitors

A

. Xarelto

. Eliquis

49
Q

Clot-dissolving drugs

A 
. Drugs that activate paslminogen 
. T-PA, u-PA, or streptokinase 
. Drugs act to break down existing clots 
. Don’t inhibit formation of new clots 
. Main complication: bleeding
50
Q

Hemophilia

A

A and B are x-linked
. Conversion of X to Xa in intrinsic pathway is impaired
. Hemarthroses: bleeding into joints
. Hematoma: hemorrhages into subQ CT or muscle

51
Q

Cofactors of coagulation that aren’t enzymes

A

. FV

. FVIII

Biochemistry (64 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions